Kefah Mokbel, Professor of Medicine at Cardiff University School of Medicine, shared on LinkedIn:
“In this cohort of heavily pretreated HR+/HER2− metastatic or recurrent breast cancer, Dato‐DXd showed limited clinical activity compared with clinical trials, particularly among patients previously treated with T‐DXd.
Nevertheless, Dato‐DXd was safely administered with toxicity management. Further real‐world studies are needed to optimize patient selection and treatment sequencing.
You can also read: Sami Mansfield: GLP-1s After Breast Cancer: A Prescription Is Not a Survivorship Plan
